Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2009-1-2
pubmed:abstractText
The thiazolidinediones (TZDs) improve tissue sensitivity to insulin in patients with type II diabetes, resulting in reduced levels of fasting blood glucose and glycated hemoglobin. However, TZDs unpredictably demonstrate adverse effects of increased body weight, fluid retention, and edema. The balance of efficacy and safety of TZD varies widely from patient to patient. Genetic variability may reveal pathophysiological pathways underlying weight gain associated with TZD therapy and due to adiposity and/or edema.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1873-3492
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
400
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
48-55
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.
pubmed:affiliation
Genomas, Inc., 67 Jefferson St, Hartford, CT, United States. g.ruano@genomas.net
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't